Published in Science on August 08, 1997
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med (1998) 3.72
Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev (1999) 3.32
Mechanisms of apoptosis. Am J Pathol (2000) 3.23
Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med (1999) 2.76
Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci U S A (1999) 2.53
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A (2000) 2.49
Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev (2000) 2.48
Life and death by death receptors. FASEB J (2009) 2.39
TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev (2002) 2.31
Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18
Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med (1999) 2.13
Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. J Exp Med (1998) 2.11
TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med (2000) 2.10
Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med (2013) 2.06
LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest (1998) 1.89
Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med (1999) 1.88
Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 1.86
Signal peptide prediction based on analysis of experimentally verified cleavage sites. Protein Sci (2004) 1.80
The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol (2000) 1.80
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med (2000) 1.77
Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis (2010) 1.71
Colorectal cancer: genetics of development and metastasis. J Gastroenterol (2006) 1.63
TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia (2002) 1.61
Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin. J Invest Dermatol (2013) 1.56
DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol (2005) 1.55
Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor. Blood (2011) 1.54
Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood (2001) 1.54
Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest (2004) 1.52
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol (2006) 1.52
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol (2009) 1.51
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Virol (2003) 1.48
Human cytomegalovirus UL144 open reading frame: sequence hypervariability in low-passage clinical isolates. J Virol (1999) 1.45
Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis. J Cell Biol (2000) 1.43
Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice. J Exp Med (2001) 1.42
Molecular optical imaging: applications leading to the development of present day therapeutics. NeuroRx (2005) 1.36
TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets (2007) 1.36
Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol (2000) 1.35
Receptor-mediated choreography of life and death. J Clin Immunol (2003) 1.33
Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol (2007) 1.33
Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells. Cancer Res (2005) 1.33
B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. Proc Natl Acad Sci U S A (2000) 1.31
How TRAIL kills cancer cells, but not normal cells. Science (1997) 1.29
Retracted Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J Biol Chem (2010) 1.29
Sendai virus infection induces apoptosis through activation of caspase-8 (FLICE) and caspase-3 (CPP32). J Virol (1999) 1.27
The Interplay between the bone and the immune system. Clin Dev Immunol (2013) 1.26
Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol (2010) 1.25
Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice. J Virol (2005) 1.24
Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J Virol (2001) 1.24
Retracted Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK. J Biol Chem (2010) 1.24
Retracted Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem (2010) 1.24
Apoptosis and cancer drug targeting. J Clin Invest (1999) 1.22
Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology (2008) 1.20
ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem (2008) 1.19
Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol Cell Biol (2003) 1.17
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res (2008) 1.17
Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res (2007) 1.14
Activation of human monocytes induces differential resistance to apoptosis with rapid down regulation of caspase-8/FLICE. Proc Natl Acad Sci U S A (1998) 1.13
TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther (2009) 1.13
Regulation of the human TRAIL gene. Cancer Biol Ther (2012) 1.12
TVB receptors for cytopathic and noncytopathic subgroups of avian leukosis viruses are functional death receptors. J Virol (2000) 1.10
Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer (2005) 1.10
Differential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamily. Cell Signal (2008) 1.09
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 1.08
The TRAIL to targeted therapy of breast cancer. Adv Cancer Res (2009) 1.08
Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ (2006) 1.07
Death receptors as targets for anti-cancer therapy. J Cell Mol Med (2008) 1.07
Retracted Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax. J Biol Chem (2010) 1.07
Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases. Clin Exp Metastasis (2007) 1.06
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis (2010) 1.06
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells. Front Oncol (2015) 1.05
Akt-phosphorylated mitogen-activated kinase-activating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4. J Biol Chem (2010) 1.04
Death receptor-ligand systems in cancer, cell death, and inflammation. Cold Spring Harb Perspect Biol (2013) 1.03
The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell (2004) 1.03
A cell surface receptor defined by a mAb mediates a unique type of cell death similar to oncosis. Proc Natl Acad Sci U S A (1998) 1.03
Targeted ovarian cancer treatment: the TRAILs of resistance. Am J Cancer Res (2011) 1.02
Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther (2011) 1.02
Effects of Chinese Jianpi herbs on cell apoptosis and related gene expression in human gastric cancer grafted onto nude mice. World J Gastroenterol (2002) 1.01
Hashimoto's Thyroiditis: From Genes to the Disease. Curr Genomics (2011) 1.01
The role of TRADD in death receptor signaling. Cell Cycle (2012) 1.00
Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol (2004) 1.00
Retracted Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand. J Gen Virol (2005) 1.00
Detection of soluble TRAIL in HBV infected patients and its clinical implications. World J Gastroenterol (2002) 0.99
PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer. J Cell Mol Med (2008) 0.99
TANK potentiates tumor necrosis factor receptor-associated factor-mediated c-Jun N-terminal kinase/stress-activated protein kinase activation through the germinal center kinase pathway. Mol Cell Biol (1999) 0.99
A cell-based high-throughput screen to identify synergistic TRAIL sensitizers. Cancer Immunol Immunother (2008) 0.98
Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes. Proc Natl Acad Sci U S A (2001) 0.98
The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms. J Virol (2002) 0.98
Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci (2010) 0.98
Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion. Recent Pat Anticancer Drug Discov (2011) 0.97
Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice. J Exp Med (2001) 0.97
Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med (2012) 0.97
NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL. BMC Cancer (2010) 0.97
The hair follicle: dying for attention. Am J Pathol (1997) 0.97
Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors. Ann Rheum Dis (1999) 0.96
Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am J Pathol (2007) 0.96
TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis (2005) 0.96
Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer (2003) 0.95
Death receptors: signaling and modulation. Science (1998) 16.95
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
Arabidopsis transcription factors: genome-wide comparative analysis among eukaryotes. Science (2000) 11.68
FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell (1995) 9.81
Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell (1995) 9.22
Mutation of a mutL homolog in hereditary colon cancer. Science (1994) 9.04
Integration of murine leukemia virus DNA depends on mitosis. EMBO J (1993) 7.62
Caspases: intracellular signaling by proteolysis. Cell (1997) 7.46
LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol (1999) 7.27
TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science (1995) 6.41
The receptor for the cytotoxic ligand TRAIL. Science (1997) 6.39
IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science (1997) 6.30
Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature (1994) 6.21
Apoptosis signaling. Annu Rev Biochem (2000) 6.18
BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 5.99
Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell (1993) 5.37
Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell (1990) 4.58
Apoptosis control by death and decoy receptors. Curr Opin Cell Biol (1999) 4.54
A T5 promoter-based transcription-translation system for the analysis of proteins in vitro and in vivo. Methods Enzymol (1987) 4.21
Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell (2000) 4.19
An induced proximity model for caspase-8 activation. J Biol Chem (1998) 4.18
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol (2001) 4.10
Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases. J Biol Chem (1996) 3.97
Promoters of Escherichia coli: a hierarchy of in vivo strength indicates alternate structures. EMBO J (1986) 3.89
Caspase activation: the induced-proximity model. Proc Natl Acad Sci U S A (1999) 3.86
Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem (1995) 3.83
Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J Biol Chem (1999) 3.81
Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell (1996) 3.81
Cloning and analysis of strong promoters is made possible by the downstream placement of a RNA termination signal. Proc Natl Acad Sci U S A (1981) 3.77
FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem (1996) 3.72
Keratinocytes as initiators of inflammation. Lancet (1991) 3.68
Thrombospondin binds falciparum malaria parasitized erythrocytes and may mediate cytoadherence. Nature (1985) 3.53
Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science (1997) 3.51
Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J Biol Chem (1997) 3.41
The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem (1990) 3.41
Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J Biol Chem (1992) 3.36
Functional dissection of Escherichia coli promoters: information in the transcribed region is involved in late steps of the overall process. EMBO J (1986) 3.33
Expression and purification of the leucine zipper and DNA-binding domains of Fos and Jun: both Fos and Jun contact DNA directly. Proc Natl Acad Sci U S A (1990) 3.31
Caspase-9 can be activated without proteolytic processing. J Biol Chem (1999) 3.20
A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem (1994) 3.13
The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem (1992) 3.13
PATRIC: the VBI PathoSystems Resource Integration Center. Nucleic Acids Res (2006) 3.06
A highly conserved enhancer in the Dlx5/Dlx6 intergenic region is the site of cross-regulatory interactions between Dlx genes in the embryonic forebrain. J Neurosci (2000) 2.98
Co-association of CD3 zeta with a receptor (CD16) for IgG Fc on human natural killer cells. Nature (1989) 2.91
The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem (1992) 2.90
RAIDD is a new 'death' adaptor molecule. Nature (1997) 2.89
Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science (1995) 2.88
Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science (1996) 2.87
Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol (2001) 2.85
Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol (2000) 2.78
Role of CED-4 in the activation of CED-3. Nature (1997) 2.76
Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol (2001) 2.75
RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. J Biol Chem (1998) 2.58
The domains of death: evolution of the apoptosis machinery. Trends Biochem Sci (1999) 2.56
Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem (1998) 2.48
Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem (1999) 2.44
Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem (1999) 2.41
The product of a fos-related gene, fra-1, binds cooperatively to the AP-1 site with Jun: transcription factor AP-1 is comprised of multiple protein complexes. Genes Dev (1989) 2.41
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol (2000) 2.29
Antisense snoRNAs: a family of nucleolar RNAs with long complementarities to rRNA. Trends Biochem Sci (1995) 2.29
LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol (2000) 2.27
Molecular cloning and functional expression of a human cDNA encoding the antimutator enzyme 8-hydroxyguanine-DNA glycosylase. Proc Natl Acad Sci U S A (1997) 2.27
Cloning and sequencing a human homolog (hMYH) of the Escherichia coli mutY gene whose function is required for the repair of oxidative DNA damage. J Bacteriol (1996) 2.26
Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex. J Biol Chem (1998) 2.25
Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol (1991) 2.24
ICE-LAP3, a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis. J Biol Chem (1996) 2.20
The cell-death machine. Curr Biol (1996) 2.18
Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med (2000) 2.18
RIP3, a novel apoptosis-inducing kinase. J Biol Chem (1999) 2.15
Isolation and characterization of human orthologs of yeast CCR4-NOT complex subunits. Nucleic Acids Res (2000) 2.13
ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J Biol Chem (1996) 2.12
TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med (2000) 2.10
Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7. J Biol Chem (1999) 2.09
A role for FADD in T cell activation and development. Immunity (1998) 2.09
lac Repressor blocks transcribing RNA polymerase and terminates transcription. Proc Natl Acad Sci U S A (1986) 2.07
MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene (2006) 2.07
Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem (1995) 2.05
A monoclonal antibody against human thrombospondin inhibits platelet aggregation. Proc Natl Acad Sci U S A (1985) 2.04
Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex. Nat Med (1999) 2.03
Subregions of a conserved part of the HIV gp41 transmembrane protein are differentially recognized by antibodies of infected individuals. EMBO J (1986) 2.01
An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nat Genet (1999) 2.01
FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J Biol Chem (1997) 2.01
ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol (2000) 2.01
A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem (1997) 2.00
A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem (1999) 1.98
Promoters recognized by Escherichia coli RNA polymerase selected by function: highly efficient promoters from bacteriophage T5. J Bacteriol (1985) 1.97
Apoptotic molecular machinery: vastly increased complexity in vertebrates revealed by genome comparisons. Science (2001) 1.97
Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet (1999) 1.96
ICEBERG: a novel inhibitor of interleukin-1beta generation. Cell (2000) 1.95
Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science (2000) 1.95